Alzheimer fibrils at atomic resolution

August 4, 2016

Elongated fibres (fibrils) of the beta-amyloid protein form the typical senile plaque present in the brains of patients with Alzheimer's disease. A European research team, working in conjunction with a team from the United States, has now succeeded in explaining the structure of the beta-amyloid peptide 1–42, which is the most important to the illness, at atomic resolution. This simplifies the targeted search for medicinal products to treat Alzheimer's dementia.

Alzheimer's disease is responsible for at least 60 percent of dementia cases worldwide. It causes enormous human suffering and is associated with high costs. A cure or causal therapy are not yet available. The reason for this, among other things, is because the exact course of the illness in the brain at a molecular level has not yet been adequately clarified.

We do know that the beta-amyloid protein plays an important role. This is a peptide that is 39 to 42 amino acids long, toxic to nerve cells and is able to form elongated fibrils (fibres). Beta-amyloid peptide 1–42 and beta-amyloid peptide 1-40 are the two main forms that appear in senile plaques. We do not know why these lead to the decay of nerve cells in the brain, but it is very interesting for the development of medications to treat Alzheimer's disease.

In a joint project between the Swiss Federal Institute of Technology in Zurich, University of Lyon, and the Goethe University in Frankfurt am Main, and in cooperation with colleagues at the University of Irvine and Brookhaven National Laboratory, researchers have succeeded in clarifying the structure of a beta-amyloid peptide 1–42 fibril at an . This fibril presents the greatest danger in this disease. The researchers also furthered the work done at the University of Chicago involving the structure of beta-amyloid monomers. Further immunological examinations prove that the investigated form of the fibrils is especially relevant to the illness.

Protein fibrils are in fact visible in electron microscope images (fig. 1), but it is very difficult to go down to an of detail. The conventional structural-biological methods required to achieve this assume that the macromolecule is present as an extremely regular crystal or in the form of individual molecules that are dissolved in water. However, fibrils are elongated structures that adhere to each other and neither form crystals, nor able to be dissolved in water.

Only solid-state nuclear magnetic resonance spectroscopy (solid-state NMR) is capable of offering a view at the atomic level in this case. New developments in methods are facilitating measurement of a network of distances between the atoms in the protein molecules that make up a fibril (Fig. 2). Extensive calculations enabled the atomic structure of the fibril to be reconstructed from these measurements.

The main part of the beta-amyloid 1-42 peptide is shaped like a double horseshoe (fig. 3). Two of the same molecules at one level are stacked onto each other to form a long fibril. Numerous oxygen bridge connections parallel to the long axis lend the fibrils their high stability.

"The structure differs fundamentally from earlier model studies, for which barely any experimental measurement data was available." explains Prof Peter Güntert, a professor of computer-aided structural biology at Goethe University.

The publications released by these European and American teams, which confirm each other, have caused great excitement in expert circle, as they have enabled a targeted, structure-based search for medicinal products that will attack the beta-amyloid . The researchers hope that the horror of this scourge of old age, first described 110 years ago by a Frankfurt-based doctor Alois Alzheimer, will finally be rendered harmless over the next one or two decades.

Explore further: Alzheimer's researchers find clues to toxic forms of amyloid beta

More information: Marielle Aulikki Wälti et al. Atomic-resolution structure of a disease-relevant Aβ(1–42) amyloid fibril, Proceedings of the National Academy of Sciences (2016). DOI: 10.1073/pnas.1600749113

Michael T. Colvin et al. Atomic Resolution Structure of Monomorphic AβAmyloid Fibrils, Journal of the American Chemical Society (2016). DOI: 10.1021/jacs.6b05129

Yiling Xiao et al. Aβ(1–42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer's disease, Nature Structural & Molecular Biology (2015). DOI: 10.1038/nsmb.2991

Related Stories

Alzheimer's researchers find clues to toxic forms of amyloid beta

June 10, 2016
Much of the research on Alzheimer's disease has focused on the amyloid beta protein, which clumps together into sticky fibrils that form deposits in the brains of people with the disease. In recent years, attention has turned ...

'Pac-Man' gene implicated in Alzheimer's disease

July 26, 2016
A gene that protects the brain from the harmful build-up of amyloid-beta, one of the causative proteins implicated in Alzheimer's disease, has been identified as a new target for therapy by NeuRA researchers.

Alzheimer protein's structure may explain its toxicity

May 7, 2015
Researchers at the University of Illinois at Chicago have determined the molecular structure of one of the proteins in the fine fibers of the brain plaques that are a hallmark of Alzheimer's disease. This molecule, called ...

Alzheimer's patients show striking individual differences in molecular basis of disease

September 12, 2013
Alzheimer's disease is thought to be caused by the buildup of abnormal, thread-like protein deposits in the brain, but little is known about the molecular structures of these so-called beta-amyloid fibrils. A study published ...

Researchers investigate the amyloid-beta peptide behind Alzheimer's

November 5, 2012
Using solid-state nuclear magnetic resonance (NMR) spectroscopy, researchers at Luleå University of Technology in collaboration with Warwick University in the UK for the first time in the world managed to analyse hydrogen ...

Recommended for you

Newly discovered biomarkers may lead to promising diagnostic tool for Alzheimer's

July 28, 2017
Diagnosing Alzheimer's disease and determining a patient's prognosis is an inexact business, and that stands in the way of better personalized care and advances in treatment.

BACE-Inhibitor successfully tested in Alzheimer's animal model

July 28, 2017
The protein amyloid beta is believed to be the major cause of Alzheimer's disease. Substances that reduce the production of amyloid beta, such as BACE inhibitors, are therefore promising candidates for new drug treatments. ...

Is it Alzheimer's or another dementia form? Why doctors need to distinguish

July 28, 2017
Alzheimer's disease now affects an estimated 5.5 million Americans, and after decades of feverish work, researchers have so far failed to find a treatment that halts or reverses the inexorable loss of memory, function and ...

Scientists use new data mining strategy to spot those at high Alzheimer's risk

July 28, 2017
The push to develop treatments for Alzheimer's disease has been a promising and disappointing endeavor over the past two decades, yielding a greater understanding of the disease yet still failing to generate successful new ...

Lifestyle changes to stave off Alzheimer's? Hints, no proof

July 20, 2017
There are no proven ways to stave off Alzheimer's, but a new report raises the prospect that avoiding nine key risks starting in childhood just might delay or even prevent about a third of dementia cases around the world.

Blood test identifies key Alzheimer's marker

July 19, 2017
A new study led by researchers at Washington University School of Medicine in St. Louis suggests that measures of amyloid beta in the blood have the potential to help identify people with altered levels of amyloid in their ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.